for the Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network IMPORTANCE Since the implementation of universal newborn screening (NBS) for cystic fibrosis (CF), the timing and magnitude of growth deficiency or its association with correlates of disease among infants with CF who underwent NBS has not been well described.
B efore newborn screening (NBS), the diagnosis of cystic fibrosis (CF) was delayed until onset of nutritional failure and many patients demonstrated persistent growth and nutritional deficiencies. 1 The advent of NBS for CF has contributed to improved clinical outcomes, including weight and stature. [2] [3] [4] [5] Improvements in growth have been steady, with median World Health Organization (WHO) weight percentiles of US infants with CF younger than 2 years increasing from less than 20% in 1993 to 40% by 2014. 6 However, despite identification of CF in the youngest patients and emphasis on early nutritional supplementation and prompt implementation of pancreatic enzyme replacement therapy (PERT), 7 growth in children with CF continues to lag significantly behind that of healthy children. These highly vulnerable infants with CF have not previously undergone evaluation in a prospective geographically diverse study powered to evaluate growth variables and potential contributing factors. Identification of these patterns is an important first step in targeting at-risk patients and could be used to measure response to novel CF therapeutics, 8, 9 because their use extends into this age group. The Baby Observational and Nutrition Study (BONUS) was a prospective multicenter study of infants with CF in which the primary aim was to examine the current state of weight gain and linear growth in the first year of life, framed within the context of historic growth patterns in CF. 10 The secondary aim of BONUS was to prospectively explore concurrent nutritional, metabolic, respiratory, infectious, and inflammatory characteristics associated with early CF anthropometric measurements.
Methods

Patients and Study Design
BONUS was conducted at 28 US Cystic Fibrosis Foundationaccredited Care Centers in the CF Foundation Therapeutic Development Network. Infants younger than 3.5 months were enrolled if they had a sweat chloride level of at least 60 mEq/L (to convert to millimoles per liter, multiply by 1) by using a quantitative pilocarpine iontophoresis test or 2 wellcharacterized CF transmembrane conductance regulator gene (CFTR [NCBI Entrez Gene 1080]) mutations. Infants with a gestational age of less than 35 weeks, with a birth weight of less than 2.5 kg, unable to take full oral feeds, or with any serious condition other than pancreatic insufficiency (PI) contributing to malabsorption or interfering with normal growth were excluded. Study visits coincided with guideline-recommended CF clinic visits (monthly until 6 months and at 8, 10, and 12 months of age). 7 Anthropometric measures (length, weight, and occipital frontal circumference) were systematically performed at each visit by certified staff. 11 Participant guardians completed 3-day diet, stool, 12 modified pain, 13 and cough 14 diaries for the infant before each study visit (eMethods 1intheSupplement). Breastfeeding frequency and duration, salt intake, vitamin and formula supplementation, and PERT dosages were included in the diet diary. Caloric and nutritional analyses were performed, and the mean was calculated for the 3-day collection. Measurement of fecal elastase levels, respiratory tract cultures, and chest radiography were performed according to Cystic Fibrosis Foundation care guidelines, 7 and the 12-month chest radiograph was scored 15 centrally by 2 independent readers. Clinical hematologic levels, chemistry, and serum vitamin levels (A, D, and E) were collected at enrollment and 6 and 12 months. Additional details can be found in eMethods 2 in the Supplement. A complete list of cites is found in the list of BONUS investigators at the end of the article. Written informed consent was obtained from all participating parents or guardians, and all participating sites received approval from their institutional review boards.
Data Presentation
We calculated z scores for attained weight, length, and occipital frontal circumference for age by using World Health Organization (WHO) standard growth curves for healthy newborns or healthy infants. 16, 17 A historic Cystic Fibrosis Foundation Patient Registry birth cohort from 1994-1995 (when only Colorado, Wyoming, and Wisconsin were conducting NBS) was compared with the contemporary BONUS birth cohort for attained weight and length. No standard definition of poor growth in infants with CF exists. For this study, persistently low weight or length were each defined as a z score of less than −1.28 (10th percentile) for more than half the yearly measurements, with at least 1 of these low measurements occurring between 6 and 12 months of age. Infants were classified as having PI if they exhibited fecal elastase levels of 200 μg/g or less or if they had 2 PI-causing CFTR mutations. 18 If the fecal elastase value was unavailable (n = 28), PERT use at study termination was used for the purposes of classification (27 of 28 infants) (eTable 1 in the Supplement).
Statistical Analysis
Differences were calculated and comparisons were made with 1-and 2-sample t tests, the Fisher exact test for categorical data, or the Pearson correlation coefficient. Linear mixed-effects models were used to estimate overall change and differences in anthropometric curves across the entire year, accounting for within-patient correlation (eMethods 2 in the Supplement). Risk ratios and 95% CIs were calculated.
Key Points
Question What is the current state of growth deficiencies among infants with cystic fibrosis after implementation of the universal newborn screen?
Findings In this study of 231 infants from 28 US Cystic Fibrosis Foundation-accredited Care Centers followed up for the first year of life, normal weight was achieved by 12 months of age (comparable to the World Health Organization cohort); however, linear growth continued to lag behind.
Meaning Since initiation of universal newborn screening for cystic fibrosis, significant improvement in nutritional status during infancy has occurred, but stunting remains common.
Results
From January (eTable 1 in the Supplement).
Anthropometrics
As extracted from medical records, birth weights of BONUS infants were statistically lower than those of WHO healthy newborns (mean z score, −0.15; 95% CI, −0.27 to −0.04), with a median birth weight of 3.2 (range, 2.5-4.4) kg. By 12 months of age, BONUS infants demonstrated increased weight gain, and weight for age was not different from that of WHO healthy infants (mean z score, −0.04; 95% CI, −0.17 to 0.09) ( Figure 1A) . Compared with the 1994-1995 birth cohort, an increase in weight for age was seen at 6 months (mean z score increase, 1.47; 95% CI, 1.24-1.69) and 12 months (mean z score increase, 0.57; 95% CI, 0.37-0.77) ( Figure 2A ). Birth lengths of BONUS infants were higher than those of WHO healthy newborns (mean z score, 0.44; 95% CI, 0.26-0.62), with a median birth length of 50.8 (range, 40.1-57.3) cm. However, length for age in BONUS infants measured per study protocol was lower than that in WHO healthy infants ( Figure 1B ) at 3, 6, and 12 months of age (12-month mean z score, −0.56; 95% CI, −0.70 to −0.42). Midparental height was available in the Cystic Fibrosis Foundation Patient Registry for 52 parent pairs, and as a group, their heights were not significantly lower than US Centers for Disease Control and Prevention 2007-2010 adult white normative values. 20 Length was improved compared with the historic cohort at 6 months (z score increase, 1.06; 95% CI, 0.82-1.30) and at 12 months (z score increase, 0.63; 95% CI, 0.41-0.86) ( Figure 2B ). Occipital frontal circumference was normal or above normal at all ages ( Figure 1C ). Figure 3A ) but not at 6 or 12 months. Feeding type was not associated with infant length at any time point ( Figure 3B ). Growth z scores had a significant and negative correlation with caloric intake among those who were not breastfed (r =−0.48 for weight; r = −0.31 for length).
Nutritional Intake and Fat-Soluble Vitamins
With use of cumulative anthropometrics through the first year, participants were categorized into low-weight and lowlength groups. Among the 222 BONUS infants with follow-up beyond 6 months, 30 (13.6%) met the study definition of low weight; 53 (23.9%), low length; and 24 (10.8%), both categories. Twenty-eight of 53 low-length infants (53%) were not categorized as low weight. Low-weight infants consumed significantly more calories than did normal-weight infants at 6 months (153 vs 101 kcal/kg/d). Low-length infants also consumed significantly more calories (131 vs 100 kcal/kg/d) ( Figures 3C and D 
Associations Between Clinical Features and Growth
The (Table) . Female BONUS infants had consistently higher z scores for weight (mean, 0.30; 95% CI, 0.06-0.54) than did male infants; of note, 72 boys (59.5%) were homozygous for Phe508del compared with 60 girls (54.5%). Infants who had been prescribed H 2 blockers alone or with proton pump inhibitors had lower weight and length. Patients prescribed proton pump inhibitors alone did not have significantly lower z scores for weight (−0.16; 95% CI, −0.47 to 0.16) or height (−0.02; 95% CI, −0.36 to 0.32). Infants with at least 1 Pseudomonas aeruginosa−positive oropharyngeal swab result had lower z scores for weight (−0.38; 95% CI, −0.65 to −0.10); infants with wheezing had a mean lower z score for length (-0.43; 95% CI, −0.76 to −0.10) than did those who did not (Table) . Other pulmonary, infectious, and inflammatory factors were not associated with differential growth in infants with CF.
The same clinical features were examined as potential risk factors for low weight and length categorization in the BONUS cohort (eTable 3 in the Supplement). Use of H 2 blockers alone demonstrated a relative risk of 2.11 (95% CI, 0.74-5.97) for low weight and 2.78 (95% CI, 1.38-5.61) for low length. Use of H 2 blockers in combination with proton pump inhibitors had a Curves indicate World Health Organization (WHO) standard growth curves for healthy infants 16 ; we calculated z scores for attained weight, length, and occipital frontal circumference (OFC) for age of infants in the BONUS cohort using the WHO standard growth curves.
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Original Investigation Research jamapediatrics.com (Reprinted) JAMA Pediatrics June 2017 Volume 171, Number 6 549 relative risk of 4.24 (95% CI, 1.62-11.11) for low weight and 2.86 (95% CI, 1.38-5.93) for low length compared with no H 2 blocker or proton pump inhibitor use. Wheezing was associated with a 1.73 times increased risk for low length (95% CI, 1.05-2.85) and a 2.06 times increased risk for low weight (95% CI, 1.03-4.15), whereas P aeruginosa infection in the first year of life was associated with low weight (relative risk, 2.31; 95% CI, 1.20-4.44) but not length (eTable 3 in the Supplement). Fecal calprotectin and blood measures of inflammation were not significantly associated with low weight or length (eFigures 2-6 and eTable 3 in the Supplement). Serum insulinlike growth factor 1 (IGF-1) levels were lower at 6 months in the BONUS cohort (mean, 51.4 ng/mL; 95% CI, 48.2-54.7 ng/mL [to convert to nanomoles per liter, multiply by 0.131) than in published norms (100 ng/mL) 23 and were even lower among infants classified as low weight (mean difference from other BONUS infants, −6.9 ng/mL; 95% CI, −14.0 to 0.3 ng/mL) and low length (mean difference compared with other infants with CF, −8.6 ng/mL; 95% CI, −14.2 to −3.1 ng/mL) ( Figure 4A and B). Serum IGF binding protein 3 levels among BONUS infants (mean, 2262.9 ng/mL; 95% CI, 2178.3-2347.5) were higher than among healthy infants at 6 months of age (1720 ng/mL), 23 but levels were lower among low-weight (mean difference, −311 ng/mL; 95% CI, −480 to −141 ng/mL) and low-length (mean difference, −358 ng/mL; 95% CI, −490 to −226 ng/mL) infants compared with their BONUS peers ( Figure 4C and D). Other demographic, diagnostic, feeding, and respiratory tract features were not associated with low weight or length categorization in the BONUS cohort. 
Feeding type
We calculated z scores for mean attained weight and length for age of infants using the the World Health Organization (WHO) standard growth curves 16 and plotted these by breastfed (BF) only, formula fed (FF) only, and both. Caloric intake by weight categorization and length categorization was calculated among exclusively FF or solid food-fed BONUS infants. Low categorization indicates that more than 50% of measurements are less than the 10th percentile of the WHO standard curve, with at least 1 such measurement occurring after 6 months of age. Error bars indicate 95% CIs. 
Cohort
We calculated z scores for mean attained weight and length for age of infants using the World Health Organization standard growth curves. 16 The historic cohort includes infants in the 1994-1995 Cystic Fibrosis Foundation Patient Registry (Registry) birth cohort. Error bars indicate 95% CIs. Percentages indicate the percentages of the cohort undergoing newborn or prenatal screening.
Discussion
We herein report, to our knowledge, the largest multicenter prospective study examining the growth and nutritional status of a cohort of infants with CF diagnosed by NBS. Although z scores for weight for age lagged behind WHO normative values at birth and during the first 6 months of age, BONUS infant z scores for weight increased to those of WHO healthy infants by 12 months. Of note, head circumference was normal at birth and throughout the first year of life. Correction in weight gain is a striking improvement compared with a 1994-1995 historic cohort, before universal NBS for CF in the United States (Figure 2 ). Of interest, the observed improvement in weight occurred regardless of feeding type (formula vs breastfeeding), consistent with prior observations. 24 Furthermore, historic markers of nutritional status, caloric and macronutrient intake, or vitamin supplementation were often higher in low-weight and low-length infants and did not predict normal growth. One could speculate that key factors in successful correction of weight include early implementation of PERT not possible before universal NBS in the United States and current aggressive approaches to nutritional supplementation.
Despite significant progress in improved weight among infants with CF, a subgroup of low-weight infants continued to falter. In this group, increased caloric intake and addition of H 2 blockers to improve enzyme efficacy did not correlate with better growth outcomes. Additional caloric and supplement intake very likely prevented more severe failure to thrive; thus, we caution that these results not be interpreted to suggest that caloric supplementation in infants with CF is not necessary. However, this subpopulation was unable to overcome growth deficits, suggesting that other factors contributed to poor weight gain and linear growth. We examined an extensive list of pulmonary, nutritional, hormonal, infectious, and inflammatory factors that might be associated with poor growth. Colonization with P aeruginosa and wheezing were associated with the highest risk for low weight or length, even in this very young and healthy population, consistent with infant CF studies in Australia. 25, 26 Despite the absence of identifiable associated inflammatory measures in this study, poor weight gain and eventual poor lung function may have a common etiology rather than a causal relationship. In contrast to our observations with weight improvement, we found persistent delay at 1 year in linear growth in most BONUS infants. Given the rigor taken in certifying BONUS 
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eMethods 2. Data Collection and Statistical Analysis
Previous or simultaneous enrollment into the CF Foundation Patient Registry was required to facilitate long term follow-up beyond one year of age. Birth weight and length were ascertained from the medical records. Stool and urine were collected at each visit for analysis of fecal calprotectin, urinary aldosterone, creatinine, and sodium at the CF Foundation Therapeutics Development Network Center for Biochemical Markers, University of Colorado, Denver, CO). Serum was collected at enrollment, 6 and 12 months for analysis of insulin-like growth factor-I (IGF-I), IGF binding protein-3 (BP-3), and inflammatory measures serum amyloid a (SAA), high sensitivity C-reactive protein (hsCRP), interleukin-8 (IL-8) and granulocytecolony stimulating factor (G-CSF) at the Center for Biochemical Markers. Blood, urine, fecal and respiratory culture samples were banked for later analyses if consent was given.
Caloric and nutritional analyses were performed using The Food Processor® software (ESHA Research V10.12, Salem OR USA) and averaged over the 3 days collection. Chest x-rays were centrally scored at the CF Foundation Therapeutics Development Network Center for Diagnostic Imaging, University of Wisconsin, Madison, WI.
For the purposes of correlating with clinical features, linear mixed effects models were used to estimate subject-specific overall change and differences in anthropometric curves across the entire year accounting for within subject correlation (compound symmetric correlation structure with a random effect for subject intercept and slope; no other covariates were included in the estimation model). All statistical analyses were performed using SAS Version 9. 
